Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis-related and exposure-related genes
Carcinoma, Renal Cell
Polymorphism, Single Nucleotide
Receptor Protein-Tyrosine Kinases
Germline variants in angiogenesis- and exposure-related genes may predict treatment response to pazopanib monotherapy in patients with RCC. If validated, these markers may explain why certain patients fail antiangiogenesis therapy and they may support the use of alternative strategies to circumvent this issue.